For Immediate Release

Chicago, IL – May 24, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Oracle (NYSE: ORCL – Free Report ), Chubb (NYSE: CB – Free Report ), AstraZeneca (NYSE: AZN – Free Report ), Estee Lauder (NYSE: EL – Free Report ) and Aflac (NYSE: AFL – Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Tuesday’s Analyst Blog:

New Research Reports for Wednesday: ORCL, CB, AZN & More

Today's Research Daily features new research reports on 16 major stocks, including Oracle (NYSE: ORCL – Free Report ), Chubb (NYSE:CB – Free Report ) and AstraZeneca (NYSE: AZN – Free Report ). You can see all of today’s research reports here >>>

Oracle shares have outperformed the Zacks Technology Sector year-to-date, gaining +16% vs. +14.9%. The company’s offerings in SaaS and PaaS have gained significant momentum in the past few quarters, which improves the company's competitive position in the red hot cloud space, particularly against salesforce.com and Workday. The introduction of Gen 2 IaaS data centers is expected to improve Oracle’s competitive standing against Amazon's AWS business. The Zacks analyst likes the company’s growing cloud market share and sees the positive momentum in this area as a notable top-line growth driver. The recent acquisition of Moat is a significant addition to the Oracle Data Cloud, which will boost ad measurement capability. However, the transition from on-premise licensing to cloud-based subscription business model will take some more time to complete, which will impact near-term results. (You can read the full research report on Oracle here >>> )

Chubb shares have outperformed the Zacks Property, Casualty and Title industry over the last three months, gaining +1% vs. -2.5%. The Zacks analyst thinks Chubb stands a good chance of taking leadership in the P&C space, benefiting from complementary products and services. Its inorganic growth story is impressive and should help it achieve higher long-term ROE. A strong capital position has helped Chubb engage in shareholder-friendly moves and invest in strategic initiatives to drive growth. Notably, the company is on track to achieve annual run-rate integration-related savings of $800 million by the end of 2018. However, exposure to cat loss and escalating expenses are major concerns. (You can read the full research report on Chubb here >>> )

AstraZeneca shares have gained +24.2% year to date, and have outperformed the Zacks Large Cap Pharma sector which has gained +10.2% over the same period, which reflects the company's activities on the acquisition and partnering fronts. Newly launched drugs should keep contributing to the top line and ease the impact of genericization. Meanwhile, cost-cutting initiatives should drive the bottom line. Streamlining operations, along with its focus on R&D, will benefit the company in the long run. The Zacks analyst likes AstraZeneca’s promising late-stage pipeline that includes immuno-oncology candidates. However, core products like Nexium and Crestor are facing generic competition, which is hurting hurt near-term earnings growth. (You can read the full research report on AstraZeneca here >>> )

Other noteworthy reports we are featuring today include Estee Lauder (NYSE: EL – Free Report ) and Aflac (NYSE:AFL – Free Report ).

Zacks' 2017 IPO Watch List

Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.

One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on ORCL - FREE

Get the full Report on CB - FREE

Get the full Report on AZN - FREE

Get the full Report on EL - FREE

Get the full Report on AFL - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Click for Free Oracle Corporation (ORCL) Stock Analysis Report >>
 
Click for Free D/B/A Chubb Limited New (CB) Stock Analysis Report >>
 
Click for Free Astrazeneca PLC (AZN) Stock Analysis Report >>
 
Click for Free Estee Lauder Companies, Inc. (The) (EL) Stock Analysis Report >>
 
Click for Free Aflac Incorporated (AFL) Stock Analysis Report >>
 
To read this article on Zacks.com click here.
 
Zacks Investment Research